The next-generation drug for severe asthma, ‘Tezpire' is soon expected to enter the Korean market.

According to industry sources, AstraZeneca Korea has submitted an application for the approval of ‘Tezspire (tezepelumab)’ in H2 to the Ministry of Food and Drug Safety and is receiving its final review.

Whether AstraZeneca will be able to continue on its lineage in the field of asthma with Tezspire after failing to list its ‘Fasenra (benralizumab)’ for reimbursement remains to be seen.

As a viable competitor to Sanofi’s ‘Dupixent (dupilumab),’ Tezspire inhibits the action of the thymic stromal lymphopoietin (TSLP), a key epithelial cytokine that sits at the top of m